23,959 Shares in Boston Scientific Corporation $BSX Purchased by Coastal Bridge Advisors LLC

Coastal Bridge Advisors LLC bought a new stake in shares of Boston Scientific Corporation (NYSE:BSX) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 23,959 shares of the medical equipment provider’s stock, valued at approximately $1,023,000.

Several other hedge funds also recently modified their holdings of the business. BlackRock Inc. bought a new stake in shares of Boston Scientific during the second quarter worth approximately $5,534,781,000. Primecap Management Co. CA bought a new position in Boston Scientific in the second quarter valued at approximately $2,156,233,000. Norges Bank acquired a new stake in Boston Scientific during the 4th quarter worth $2,199,395,000. Jupiter Topco LLC acquired a new stake in Boston Scientific during the 2nd quarter worth $803,357,000. Finally, Bank of America Corp DE bought a new stake in shares of Boston Scientific during the 2nd quarter valued at $556,026,000. Institutional investors own 89.07% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on BSX. Zacks Research downgraded Boston Scientific from a “hold” rating to a “strong sell” rating in a research note on Friday, June 5th. Bank of America decreased their price objective on Boston Scientific from $105.00 to $68.00 and set a “buy” rating for the company in a research note on Monday, May 18th. Robert W. Baird set a $56.00 price objective on Boston Scientific in a report on Thursday, July 30th. Oppenheimer cut their target price on Boston Scientific from $90.00 to $85.00 and set an “outperform” rating on the stock in a research note on Monday, July 27th. Finally, Barclays reduced their target price on Boston Scientific from $96.00 to $89.00 and set an “overweight” rating on the stock in a report on Thursday, May 28th. Twenty-four research analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $71.62.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, Director Edward J. Ludwig acquired 5,000 shares of the business’s stock in a transaction dated Friday, July 31st. The shares were acquired at an average price of $45.48 per share, for a total transaction of $227,400.00. Following the acquisition, the director directly owned 30,359 shares of the company’s stock, valued at approximately $1,380,727.32. This trade represents a 19.72% increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Michael F. Mahoney bought 186,240 shares of the stock in a transaction that occurred on Monday, August 3rd. The shares were acquired at an average cost of $48.33 per share, with a total value of $9,000,979.20. Following the completion of the purchase, the chief executive officer owned 1,590,024 shares in the company, valued at $76,845,859.92. This represents a 13.27% increase in their position. The SEC filing for this purchase provides additional information. Over the last ninety days, insiders acquired 194,522 shares of company stock valued at $9,385,210. Company insiders own 0.34% of the company’s stock.

Boston Scientific Trading Down 3.2%

Shares of NYSE BSX opened at $46.64 on Friday. The company’s fifty day moving average is $46.53 and its 200-day moving average is $56.72. The stock has a market cap of $67.59 billion, a price-to-earnings ratio of 18.88, a P/E/G ratio of 1.05 and a beta of 0.56. Boston Scientific Corporation has a twelve month low of $42.20 and a twelve month high of $109.50. The company has a quick ratio of 0.74, a current ratio of 1.24 and a debt-to-equity ratio of 0.43.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, beating analysts’ consensus estimates of $0.83 by $0.03. The business had revenue of $5.44 billion during the quarter, compared to analysts’ expectations of $5.38 billion. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The firm’s quarterly revenue was up 7.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.75 EPS. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Equities research analysts predict that Boston Scientific Corporation will post 3.3 EPS for the current year.

Boston Scientific declared that its board has authorized a stock buyback plan on Monday, May 18th that authorizes the company to repurchase $5.00 billion in shares. This repurchase authorization authorizes the medical equipment provider to buy up to 6.4% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s leadership believes its shares are undervalued.

Key Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Director Susan E. Morano reportedly purchased additional Boston Scientific shares, signaling confidence from an insider while the stock is near its recent lows. Top Boston Scientific Insider Makes Bold New Share Grab
• Neutral Sentiment: The company’s latest quarterly results had been stronger than expected, with adjusted EPS and revenue exceeding consensus estimates and revenue rising year over year. However, that earnings momentum may provide limited near-term support while the cyber incident remains unresolved.
• Negative Sentiment: Boston Scientific said the cyberattack disrupted information systems used to process customer orders and ship products worldwide. The company is working to restore access, but the timing of a full recovery remains unclear, raising the risk of shipment delays, lost sales, remediation costs and weaker near-term results. Boston Scientific hit by cyberattack, global operations affected
• Negative Sentiment: The cybersecurity disruption comes alongside reports of a cardiac-device recall, increasing investor concerns about operational reliability, regulatory exposure and pressure on Boston Scientific’s growth outlook. The company has not yet quantified the financial impact of either issue. Boston Scientific hit with cardiac device recall

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.